个人内认知变异与阿尔茨海默病风险的关联:系统性审查
Fini Chang1,2, Fareshte Erani1, Daniel Landaverde3
1Department of Psychiatry, University of California San Diego, La Jolla, CA, USA.
The Clinical neuropsychologist
|August 23, 2025
概括
个人内认知变化 (IIV) 或表现不一致和分散与阿尔茨海默病 (AD) 风险和认知衰退有关. 较高的IIV可能表明AD痴呆的风险和严重程度增加.
科学领域:
- 神经科学
- 认知心理学
- 老年学
背景情况:
- 认知个体内变化 (IIV) 描述了个体在认知任务中的表现波动.
- 虽然在认知衰老方面进行了研究,但IIV在阿尔茨海默病 (AD) 中的作用是一个新兴的研究领域.
- IIV包括不一致性 (分数的变化) 和分散性 (分数的分布).
研究的目的:
- 在阿尔茨海默病 (AD) 风险方面综合研究.
- 评估 IIV 在区分认知阶段的实用性.
- 探索IIV和AD生物标志物之间的关联.
主要方法:
- 在PubMed,PsycINFO和Web of Science中进行系统的文献审查.
- 遵守PRISMA研究选择指南.
- 包括44项研究,研究IIV对AD风险,认知障碍和生物标志物的影响.
主要成果:
- 基于不一致的IIV与认知障碍严重程度的增加相关,特别是在轻度认知障碍 (MCI) 和AD痴呆症中.
- 基于分散的IIV研究显示出混合的结果,但通常将较高的IIV与MCI和发病痴呆症的预测联系起来.
- 这两种IIV指标都表明与AD生物标志物 (如粉样性病) 的关联.
结论:
- 认知不一致和分散的测量与认知衰退和AD生物标志物有关,独立于平均认知表现.
- IIV显示有潜力识别患痴呆风险的个人.
- 需要对IIV评估方法进行标准化,以便在研究中进行更清晰的比较.
更多相关视频
04:41Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
Published on: January 9, 2020
19.0K
06:46Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
12.3K
相关概念视频
01:26Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
01:30Cognitive Development During Adulthood
267
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
267
01:30Biological Influences on Intelligence
213
Intelligence is often thought to be linked to brain size, but the relationship is more complex than that. While brain size does correlate modestly with some abilities, like verbal skills, the connection is weaker for others, such as spatial reasoning. Other factors, like brain structure, also play crucial roles. For instance, despite Einstein's smaller-than-average brain, his parietal cortex, which is involved in spatial reasoning, was 15% wider, suggesting that neural density might matter...
213
01:30Dementia
165
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
165